Increased midgestational IFN-γ, IL-4 and IL-5 in women bearing a child with autism: A case-control study by Goines, Paula E et al.
RESEARCH Open Access
Increased midgestational IFN-g, IL-4 and IL-5
in women bearing a child with autism:
A case-control study
Paula E Goines
1,2, Lisa A Croen
3, Daniel Braunschweig
1,2, Cathleen K Yoshida
3, Judith Grether
4, Robin Hansen
2,5,
Martin Kharrazi
6, Paul Ashwood
2,7 and Judy Van de Water
1,2*
Abstract
Background: Immune anomalies have been documented in individuals with autism spectrum disorders (ASDs)
and their family members. It is unknown whether the maternal immune profile during pregnancy is associated
with the risk of bearing a child with ASD or other neurodevelopmental disorders.
Methods: Using Luminex technology, levels of 17 cytokines and chemokines were measured in banked serum
collected from women at 15 to 19 weeks of gestation who gave birth to a child ultimately diagnosed with (1) ASD
(n = 84), (2) a developmental delay (DD) but not autism (n = 49) or (3) no known developmental disability (general
population (GP); n = 159). ASD and DD risk associated with maternal cytokine and chemokine levels was estimated
by using multivariable logistic regression analysis.
Results: Elevated concentrations of IFN-g, IL-4 and IL-5 in midgestation maternal serum were significantly
associated with a 50% increased risk of ASD, regardless of ASD onset type and the presence of intellectual
disability. By contrast, elevated concentrations of IL-2, IL-4 and IL-6 were significantly associated with an increased
risk of DD without autism.
Conclusion: The profile of elevated serum IFN-g, IL-4 and IL-5 was more common in women who gave birth to a
child subsequently diagnosed with ASD. An alternative profile of increased IL-2, IL-4 and IL-6 was more common
for women who gave birth to a child subsequently diagnosed with DD without autism. Further investigation is
needed to characterize the relationship between these divergent maternal immunological phenotypes and to
evaluate their effect on neurodevelopment.
Background
Autism spectrum disorders (ASDs) are a heterogeneous
group of neurodevelopmental diseases that manifest in
early childhood. Individuals with ASD demonstrate vary-
ing degrees of social impairments, deficits in language
and communication and stereotypic and repetitive beha-
viors [1]. There are no clear biological markers for ASD,
and current diagnosis relies entirely on behavioral criteria
[2,3]. Little is known about the pathology and etiology of
the disorders, though genetic, neurologic, environmental
and/or immune factors are likely involved [4]. Recent
epidemiologic data suggest that approximately 1 in 100
children is diagnosed with an ASD [5,6], highlighting the
urgent need for better understanding of this complex
disorder.
Evidence has linked various types of maternal immune
activation and dysregulation to behavioral disorders,
including ASD [7,8]. Mothers of children with ASD have
been reported to have a higher incidence of allergic and
autoimmune diseases compared to mothers of typically
developing children [9-11]. Furthermore, some mothers
harbor circulating antibodies that can bind to brain
proteins [12-15]. Prenatal immune challenge, such as a
bacterial or viral infection, has also been related to beha-
vioral disorders in offspring in both epidemiological stu-
dies and animal models [16]. Murine models have shown
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any medium, provided the original work is properly cited.that exposure to influenza [17], lipopolysaccharide (LPS)
[18] and polyinosinic:polycytidylic acid (poly(I:C)) [17,19]
during pregnancy results in offspring with altered beha-
vioral phenotypes and brain histopathology, which may be
related to aspects of ASD.
The impact of maternal immune activation on the fetal
compartment is mediated in part by cytokines and chemo-
kines [7,18,19]. Cytokines and chemokines are proteins
that control the intensity, duration and type of immune
response. Prenatal exposure to altered levels of cytokines
such as IL-2 [20] and IL-6 [21] is sufficient to induce
learning disabilities and behavioral changes in murine off-
spring. Maternal cytokines may affect the fetal compart-
ment directly, as IL-6 has been shown to cross the human
placenta (unlike many other cytokines) [22], or indirectly
through stimulation of placental cells, which may alter the
placental environment and thereby impact the fetus [7].
Few studies have examined midgestational cytokine
levels in mothers and ensuing behavioral outcomes in
children. We conducted a case-control study using
archived maternal blood samples collected during the
period from 15 to 19 weeks of gestation to investigate the
potential association between serum cytokine profiles
and the risk of bearing a child subsequently diagnosed
with a neurodevelopmental disorder. We demonstrate
the presence of divergent cytokine profiles in serum
taken during the second trimester of pregnancy from
mothers bearing (1) a child with ASD, (2) a child with a
developmental delay (DD) other than ASD or (3) a child
from the general population with no known developmen-
tal deficiencies (GP).
Methods
Subjects
The study sample was based on the Early Markers for
Autism (EMA) Study. The EMA Study is a population-
based, nested case-control study designed to evaluate bio-
logic markers of susceptibility and exposure in archived
maternal midpregnancy and neonatal blood specimens
from the same mother-baby pairs. The study subjects are
women residing in Orange County, California, who were
pregnant in 2000 and 2001 and enrolled in the state’sP r e -
natal Expanded AFP Screening Program [15]. Briefly, three
groups were identified: mothers of children with autism
spectrum disorder (ASD), mothers of children with DD
but not ASD and mothers of GP children. Children with
ASD or DD were ascertained from client records obtained
from the Regional Center of Orange County. This is one
of the 21 regional centers operated by the California
Department of Developmental Services (DDS), which are
designed to coordinate services for persons with autism
and other developmental disabilities. Clients receiving
DDS services for ASD or suspected ASD were ascertained
as possible subjects for inclusion in this study. Other
subjects with moderate to profound developmental dis-
abilities but not ASD (specifically children with an IQ <70
b a s e do ns t a n d a r d i z e dt e s t s )w e r ea s c e r t a i n e da so t h e r
possible DD cases. Diagnoses were confirmed by expert
review of all ASD and DD cases as described in the next
subsection. GP controls were randomly sampled from the
birth certificate files and frequency-matched to ASD cases
by sex, birth month and birth year at a 2:1 ratio. All past
or current DDS/regional center clients were excluded
from the GP population. All study procedures were
approved by the institutional review boards of the Califor-
nia Health and Human Services Agency and Kaiser Per-
manente Northern California.
Diagnostic verification
After subjects were ascertained from the Regional Center
Orange County, ASD and DD diagnoses were verified by
trained medical record abstractors following a protocol
initially developed by the Metropolitan Atlanta Develop-
mental Disabilities Surveillance Program [23]. Medical
record abstractors compiled detailed diagnostic and clini-
cal data from the Regional Center Orange County records
for all children initially ascertained as possibly having ASD
or DD. Expert clinical review of abstracted data was then
conducted by a developmental pediatrician to confirm the
ASD or DD diagnoses for this study using Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) criteria. Children with ASD were further cate-
gorized on the basis of disease onset type and cognitive
status (presence or absence of intellectual disability (ID) in
addition to ASD) using the DSM-IV criteria. Onset type
was determined by parental report or clinical observations
derived from chart reviews and categorized as “early” (no
statement of loss of social and/or language skills, or skill
plateau without actual loss), “regressive” (clear loss of pre-
viously acquired language and/or social skills) or unable to
discern from the record review. The ID determination
among ASD subjects was based on composite scores on
standardized cognitive and functional tests (with ID: com-
posite score <70; without ID: all scores ≥70 or some scores
<70 and others ≥70; unknown: no standardized scores in
chart). The final analytic sample consisted of 84 children
with ASD (Table 1), 49 children with ID but not ASD
(DD) (mild [DSM-IV Text Revision 317] (n = 20), moder-
ate [DSM-IV Text Revision 318.0] (n = 12), severe [DSM-
IV Text Revision 318.1] (n = 11), profound [DSM-IV Text
Revision 318.2] (n = 3), unspecified [DSM-IV Text Revi-
sion 319] (n = 3), known etiology (n = 29) or unknown
etiology (n = 20)) and 159 GP controls.
Specimen collection
Maternal midpregnancy serum specimens were retrieved
from the Project Baby’s Breath prenatal screening speci-
men archive maintained by the California Genetic Disease
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Health. As part of the screening program, venous blood
was collected at 15 to 19 weeks’ gestation in serum separa-
tor tubes by obstetrical care service providers and under-
went expanded a-fetoprotein screening at a single regional
laboratory, typically within seven days of collection (med-
ian time = 3 days). During transit via the US Postal Service
to the regional screening laboratory, no effort was made to
control the temperature of the specimens. After testing,
leftover specimens were kept under refrigeration for 1 to
2 days and then stored at -20°C. Aliquots of the samples
used for this study were stored at -80°C until use with no
freeze-thaws prior to testing. All samples were exposed to
the same collection and storage protocols.
Cytokine measurement
Serum concentrations of 17 cytokines and chemokines,
including eotaxin, granulocyte macrophage colony-stimu-
lating factor (GM-CSF), IFN-g,I L - 1 0 ,I L - 1 2 ,I L - 1 b,I L - 2 ,
IL-4, IL-5, IL-6, IL-8, IFN-g-induced protein 10, macro-
phage inflammatory protein (MIP)-1a, MIP-1b, RANTES
and TNF-a were determined using a commercially avail-
able multiplex bead-based kit (BioSource Human Bead
Kit; Invitrogen, Carlsbad, CA, USA). The assay was carried
out in accordance with the protocols provided by the
manufacturer. Briefly, 50 μL of serum was incubated with
anti-cytokine-conjugated beads in a 96-well filter-bot-
tomed plate on a plate shaker. After two hours, the beads
were washed using a vacuum manifold, and biotin-conju-
gated detection antibodies were added for one-hour incu-
bation. Following a repeat of the washing step, beads were
incubated with streptavidin phycoerythrin for 30 minutes.
The plates were then read on a Bio-Plex 100 system (Bio-
Rad Laboratories, Hercules, CA, USA) and analyzed using
Bio-Plex Manager software (Bio-Rad Laboratories) with a
five-point standard curve. Reference samples were run on
each plate to determine assay consistency.
Statistical analysis
The distribution of the cytokine concentration values was
skewed, and natural log transformation was used to
approximate normality. To examine the association of
cytokine levels with developmental outcomes after
adjustment for possible confounders, we fit separate
logistic regression models for ASD vs. GP, ASD vs. DD
and DD vs. GP. Case vs. control status was regressed on
natural log-transformed cytokine levels with adjustment
for several covariates related to the maternal blood draw
(maternal weight and gestational age at time of draw) or
associated with autism in previous epidemiologic studies
(maternal age, race, ethnicity and country of origin).
Separate models were run for each cytokine. For all cyto-
kine values that were below the limit of detection (LOD),
we assigned a value of LOD/2 prior to log transforma-
tion. Fisher’s exact tests were used to determine whether
there were differences between groups in the proportion
of subjects falling within the LOD for each cytokine.
Finally, the correlation of individual cytokine levels was
tested separately for cases and controls on the basis of
the Pearson correlation coefficient.
Results
A few demographic differences were found between
the case and control populations. Compared with the
GP controls, the parents of children with ASD were
older and the mothers were more likely to be non-His-
panic and born in the United States (Table 2). No dif-
ferences were observed between the ASD and GP
groups with regard to plurality (that is, whether the
child was a single birth or one member of a multiple
birth), maternal parity (the number of children pre-
viously delivered by the mother), maternal weight at
blood draw, and child gender (due to matching). Com-
pared to the DD group, children with ASD were more
likely to be male and first-born and their mothers were
more likely to be older, non-Hispanic and born in the
United States (Table 2). Children in the DD group
w e r em o r el i k e l yt ob em a l ec o m p a r e dt oG Pc o n t r o l
children (Table 2).
Cytokine levels measured in maternal serum samples
were adjusted for covariates, including gestational age at
the time of specimen collection and maternal weight,
age, race, ethnicity and country of birth. These adjust-
ments were designed to eliminate variations in cytokine
levels related to these factors. Additional file 1 presents
the regression results for the potential confounders
included in the multivariate models, and Additional file 2
shows the crude unadjusted odds ratios.
Table 1 Classification of autism cases in the Early
Markers for Autism study
a
Autism spectrum disorder subgroups Number of subjects
Total 84
Phenotype
Autism 55
Asperger’s syndrome 0
PDD-NOS 5
Unknown 24
Onset type
Early onset 64
Regressive 17
Unknown 3
Intellectual disability
Yes 34
No 30
Unknown 20
aPDD-NOS: pervasive developmental disorder not otherwise specified.
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a one-unit increase (on the natural log scale) in maternal
midpregnancy serum IFN-g was associated with an
approximate 50% increased risk of ASD relative to GP
controls (odds ratio (OR) = 1.52, 95% confidence interval
(95% CI) = 1.19 to 1.93) (Table 3 and Figure 1). This
increase was observed regardless of whether the child
had the regressive form (ORregressive = 1.77, 95% CI =
1.07 to 2.93) or the early-onset form (ORearly onset =1 . 5 2 ,
95% CI = 1.15 to 2.01) of the disorder and regardless of
whether ASD occurred in the presence (ORID =1 . 5 6 ,
95% CI = 1.02 to 2.38) or absence (ORno ID = 1.45, 95%
CI = 1.04 to 2.03) of ID. Additionally, significantly more
subjects in the ASD group were above the LOD for IFN-g
compared to GP subjects (P = 0.017 and P = 0.06 for the
ASD and GP groups, respectively, compared to the DD
group) (Additional file 3). The cytokines IL-4 (OR = 1.51,
95% CI = 1.12 to 2.03) and IL-5 (OR = 1.45, 95% CI =
1.07 to 1.98) were similarly associated with an approxi-
mate 50% increased risk of ASD relative to GP controls
(Table 3 and Figures 2 and 3), regardless of onset type
(IL-4: ORregressive = 1.86 (95% CI = 1.03 to 3.35), ORearly
onset = 1.47 (95% CI = 1.04 to 2.09), IL-5: ORregressive =
1.65 (95% CI = 0.99 to 2.75) and ORearly onset =1 . 5 2( 9 5 %
CI = 1.02 to 2.27)) or the presence of ID (IL-4: ORID =
1.54 (95% CI = 0.94 to 2.52), ORno ID = 1.40 (95% CI =
0.93 to 2.10), IL-5: ORID = 1.45 (95% CI = 0.84 to 2.52)
and ORno ID = 1.50 (95% CI = 0.97 to 2.30)). Higher mid-
pregnancy levels of IFN-g and IL-5 were also associated
with an increased risk of ASD relative to DD controls,
although the risk estimates did not achieve statistical sig-
nificance (Table 3).
In the DD group, a one-unit increase (on the natural log
scale) in midpregnancy serum concentrations of IL-2
(OR = 1.72, 95% CI = 1.12 to 2.64), IL-4 (OR = 2.18,
95% CI = 1.24 to 3.85) and IL-6 (OR = 1.22, 95% CI =
1.01 to 1.48) was associated with increased risk of DD
relative to GP controls in adjusted analyses (Table 3 and
Figures 2, 4 and 5). Finally, the risk for both ASD and
DD increased with increasing levels of IL-10 relative to
GP controls, but risk estimates were of borderline signif-
icance (Table 3).
Finally, Pearson correlation coefficients were used to
determine which cytokines were elevated or reduced
Table 2 Characteristics of the Early Markers for Autism study population
a
Characteristics ASD
(N = 84)
DD
(N = 49)
GP
(N = 159)
ASD vs. GP ASD vs. DD DD vs. GP
n % n % n % P value P value P value
Gender 0.91 0.0003 <0.0001
Male 73 86.9 29 59.2 139 87.4
Female 11 13.1 20 40.8 20 12.6
Plurality 0.42 1.0 0.34
Singleton 81 96.4 47 95.9 156 98.1
Multiple 3 3.6 2 4.1 3 1.9
Parity 0.05 0.24
Primiparous 42 50.0 16 32.7 67 42.1 0.24
Multiparous 42 50.0 33 67.3 92 57.9
Mother’s race 0.06 0.63 0.62
Caucasian 57 67.9 37 75.5 126 79.2
Asian 19 22.6 9 18.4 28 17.6
Other 6 7.1 3 6.1 5 3.1
Missing 2 2.4 0 0 0 0
Mother’s ethnicity 0.0007 0.0001 0.17
Hispanic 20 23.8 28 57.1 73 45.9
Non-Hispanic 64 76.2 21 42.9 86 54.1
Mother’s birth country <0.0001 <0.0001 0.33
United States 45 53.6 16 32.7 71 44.7
Mexico 9 10.7 22 44.9 58 36.5
Other 30 35.7 11 22.4 30 18.9
Mean maternal age, years (±SD) 30.9 (5.2) 28.3 (5.2) 28.2 (5.5) 0.0003 0.006 0.87
Mean paternal age, years (±SD) 34.0 (6.3) 33.0 (7.9) 31.0 (6.5) 0.001 0.41 0.14
Mean last recorded maternal weight prior to blood draw, lb (±SD) 145.1(26.7) 149.1(38.7) 146.9 (33.8) 0.65 0.53 0.56
aASD: autism spectrum disorder; DD: developmental delay; GP: general population.
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given that IFN-g and IL-4 and IL-5, commonly thought
to be counterregulatory cytokines, were elevated in
mothers bearing a child with ASD. This analysis was
designed to determine whether these cytokines were
elevated in the same individuals or whether they repre-
s e n t e dt w os u b g r o u p s :o n ew i t hh i g hl e v e l so fI F N - g
and one with high levels of IL-4 and IL-5. Maternal
serum IFN-g, IL-4 and IL-5 levels were significantly cor-
related in the ASD group (regardless of onset type and
cognitive status), demonstrating that IFN-g was indeed
elevated alongside IL-4 and IL-5. These cytokines were
also significantly correlated in the GP group, although
the correlation between IFN-g and IL-4 or IL-5 was not
a ss t r o n ga si nt h eA S Dg r o u p( T a b l e4 ) .W h i l eI L - 4
was significantly correlated with IL-5 in the DD group,
there was no correlation between maternal serum IFN-g
and either IL-4 or IL-5 in this group (Table 4). IL-4
was also significantly positively correlated with IL-2 in
all groups and with IL-6 in the ASD early-onset and
ASD without ID subgroups. Finally, IL-6 and IL-2 were
positively correlated in the GP group only (Table 4).
The differences across study groups in the strength of
the correlations may be partly explained by the underly-
ing structure of the data (that is, the large percentage of
concentrations below the LOD for some cytokines) and
thus should be interpreted with caution.
Discussion
In the present study, we characterized levels of cytokines
and chemokines in archived maternal serum collected
during midpregnancy and analyzed whether these levels
were related to ASD and DD outcomes in the child. We
have provided evidence for increased IL-4, IL-5 and
IFN-g in mothers bearing a child with ASD. In contrast,
mothers bearing a child with DD but not ASD demon-
strated increased levels of the cytokines IL-2, IL-4, IL-6
and GM-CSF as well as the chemokine MIP-1a.T h e s e
contrasting immune profiles described in the ASD and
DD groups indicate that different maternal immune pro-
files during pregnancy may be linked to divergent neu-
rodevelopmental outcomes in the child. The results
from both the ASD and DD groups suggest possible ele-
vation in IL-10 relative to the GP controls. This finding
is interesting, given that IL-10 is an immunomodulatory
cytokine that may be expressed to counteract the effects
of inflammatory cytokines.
Maternal immune activity downregulated during
pregnancy
The maternal immune system is uniquely regulated dur-
ing pregnancy to optimize the gestational environment
of the fetus [24]. Primarily, it must be poised to protect
the mother and fetus from pathogens and other poten-
tially harmful environmental factors. Simultaneously,
Table 3 Risk associated with a one-unit increase in the natural log-transformed concentration of cytokines and
chemokines measured in midpregnancy maternal serum in the Early Markers for Autism study
a
ASD mothers vs. GP mothers ASD mothers vs. DD mothers DD mothers vs. GP mothers
Analyte ORadj 95% CI ORadj 95% CI ORadj 95% CI
GM-CSF 1.06 0.88 to 1.28 0.66 0.44 to 1.00 1.28 0.95 to 1.73
IFN-g 1.52 1.19 to 1.93 1.46 0.94 to 2.26 1.42 0.99 to 2.05
IL-10 1.37 1.00 to 1.87 1.40 0.76 to 2.61 1.65 1.00 to 2.72
IL-12 0.93 0.58 to 1.47 0.39 0.13 to 1.17 0.82 0.42 to 1.62
IL-1b 0.98 0.83 to 1.15 0.84 0.61 to 1.17 1.04 0.81 to 1.32
IL-2 1.22 0.96 to 1.57 1.31 0.77 to 2.21 1.72 1.12 to 2.64
IL-4 1.51 1.12 to 2.03 1.19 0.70 to 2.03 2.18 1.24 to 3.85
IL-5 1.45 1.07 to 1.98 1.70 0.87 to 3.34 1.25 0.72 to 2.18
IL-6 1.10 0.97 to 1.26 0.79 0.62 to 1.02 1.22 1.01 to 1.48
TNF-a 1.07 0.85 to 1.35 0.66 0.42 to 1.04 1.27 0.93 to 1.74
IL-8 0.96 0.80 to 1.15 0.88 0.65 to 1.18 1.17 0.91 to 1.51
Eotaxin 1.18 0.79 to 1.74 0.72 0.38 to 1.37 1.25 0.65 to 2.42
IP-10 1.16 0.74 to 1.81 0.95 0.46 to 1.97 0.70 0.39 to 1.27
MCP-1 1.06 0.75 to 1.50 0.83 0.45 to 1.53 1.15 0.75 to 1.77
MIP-1a 1.11 0.94 to 1.31 0.87 0.61 to 1.23 1.10 0.86 to 1.41
MIP-1b 1.10 0.93 to 1.30 0.79 0.53 to 1.17 1.16 0.89 to 1.52
RANTES 0.92 0.65 to 1.31 0.97 0.44 to 2.14 0.98 0.55 to 1.76
aASD: autism spectrum disorder; GP: general population; DD: developmental delay; ORadj: adjusted odds ratio; 95% CI: 95% confidence interval; GM-CSF:
granulocyte macrophage colony-stimulating factor; MIP-1: macrophage inflammatory protein; MCP-1: monocyte chemotactic protein-1; IP-10: IFN-g-induced
protein 10; RANTES: regulated upon activation, normal T cell expressed and secreted. Results are adjusted for maternal weight and gestational age of the fetus at
the time of specimen collection, as well as for maternal age, race, ethnicity and country of origin.
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suppressed to avoid rejection of the fetus as a foreign
allograft [25]. Evidence suggests that under normal cir-
cumstances, pregnancy shifts the maternal immune sys-
tem toward a more tolerant, low inflammatory state that
involves decreased production of cytokines such as IL-6
and IFN-g and increased production of the more regula-
tory cytokines, including IL-4, IL-5 and IL-10 [26-29].
Mothers of children with ASD and DD demonstrated
increased levels of the inflammatory cytokines IFN-g
and IL-6, respectively, which may be indicative of an
atypical immune state during gestation.
Proper maternal immune regulation is important for
healthy fetal development
Dramatic changes in maternal immune homeostasis dur-
ing pregnancy (in response to infection, disease or other
environmental influences) are associated with complica-
tions such as miscarriage, preterm delivery and pree-
clampsia [30]. Maternal immune responses can also
affect the development of the fetal nervous system
[31,32]. Epidemiological studies have suggested that pre-
natal infections may be related to neurological disorders
such as schizophrenia and autism [33,34]. Furthermore,
animal models have repeatedly demonstrated that robust
maternal immune responses during pregnancy can alter
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Figure 1 Midgestational serum IFN-g. Scatterplots of natural log-
transformed levels of serum IFN-g in mothers bearing a child with
autism spectrum disorder (AU) or a developmental disability other
than ASD (DD) compared with a general population control (GP).
Each dot represents a single individual. Bars represent the medians
and interquartile ranges.
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Figure 2 Midgestational serum IL-4. Scatterplots of natural log-
transformed levels of serum IL-4 in mothers bearing a child with
autism spectrum disorder (AU) or a developmental disability other
than ASD (DD) compared with a general population control (GP).
Each dot represents a single individual. Bars represent the medians
and interquartile ranges.
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Page 6 of 11offspring behavior and brain histopathology [17,19,
35-37]. Various cytokines, including IL-6 and IL-2, have
been shown to mediate some of these effects [18,20,21].
We suggest that atypical maternal immune function dur-
ing pregnancy may be related to ASD or DD outcomes
among children.
Mothers bearing a child with ASD had increased levels of
IFN-g, IL-4 and IL-5
In the current study, mothers bearing a child with ASD
had significantly increased levels of serum IFN-g,I L - 4
and IL-5. IFN-g, the most dramatically elevated cytokine
in this population, is involved in aspects of defense
against intracellular pathogens, tumor surveillance, auto-
immunity, allergy and pregnancy. Peripheral IFN-g levels
are low in healthy pregnancies, and increased produc-
tion of peripheral IFN-g is often related to complications
such as preeclampsia [38]. IFN-g is produced by a subset
of activated T cells, though its primary source is natural
killer (NK) cells. During pregnancy, a unique population
of IFN-g-producing NK cells accumulates in the uterus,
w h e r et h e yh a v eav i t a lr o l ei np l a c e n t a ld e v e l o p m e n t
[39]. The increased levels of serum IFN-g observed in
mothers bearing a child with ASD may be indicative of
imbalanced immune function at the maternal-fetal inter-
face, which could lead to improper placental formation
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Figure 3 Midgestational serum IL-5. Scatterplots of natural log-
transformed levels of serum IL-5 in mothers bearing a child with
autism spectrum disorder (AU) or a developmental disability other
than ASD (DD) compared with a general population control (GP).
Each dot represents a single individual. Bars represent the medians
and interquartile ranges.
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Figure 4 Midgestational serum IL-6. Scatterplots of natural log-
transformed levels of serum IL-6 in mothers bearing a child with
autism spectrum disorder (AU) or a developmental disability other
than ASD (DD) compared with a general population control (GP).
Each dot represents a single individual. Bars represent the medians
and interquartile ranges.
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Alternatively, increased serum IFN-g may be due to per-
ipheral immune activity, including a response to infec-
tion, or to an immune-mediated disorder. Interestingly,
a recent examination of archived neonatal blood spots
from children with ASD revealed no elevation in patho-
gen-specific immunoglobulin G (IgG) levels relative to
controls, suggesting that prenatal infection may not be
involved [40].
Epidemiological data previously reported by our group
indicated a higher prevalence of allergy and asthma dur-
ing pregnancy in mothers of children with ASD [11].
That 2005 study examined physician-diagnosed medical
conditions in over 2,500 women enrolled in the Kaiser
Permanente Medical Care Program. Interestingly, the
midpregnancy cytokine profile we describe in the ASD
group in the present study (increased IL-4, IL-5 and IFN-
g) may be consistent with an allergic asthma clinical phe-
notype [41-44]. While IL-4 and IL-5 are known to be
upregulated in allergic asthma, IFN-g is generally thought
to be downregulated [45]. However, several reports have
shown increased production of IFN-g in addition to IL-4
and IL-5 in allergic asthma [41-44]. This has also been
observed during pregnancy in women with asthma, when
higher levels of IFN-g correlated with worsening maternal
and fetal health [43]. Future studies should address the
impact of prenatal allergy and asthma on fetal neurode-
velopment and further explore the possible connection to
behavioral disorders.
Alternative cytokine profile in mothers bearing a child
with a developmental delay
We noted that mothers bearing a child with DD but not
ASD demonstrated a different midgestational immune
profile. The risk of DD was associated with higher levels
of the cytokines IL-2, IL-4 and IL-6. Interestingly, IL-6 is
part of a cytokine family with well-defined neurological
impacts [46]. Extensive evidence links prenatal immune
responses involving increased production of inflamma-
tory cytokines such as IL-6 to pregnancy complications
and neurological abnormalities among offspring [30,47].
Mouse models have shown that prenatal exposure to IL-
6 or mimics of infectious agents such as LPS or poly(I:C)
can induce behavioral changes and brain abnormalities
among offspring [18,19,21,48]. Similarly, prenatal expo-
sure to high levels of IL-2 has been shown to induce
behavioral differences in murine models [20]. On the
basis of these animal studies, it has been suggested that
prenatal exposure to these inflammatory conditions may
be relevant to the development of autism [20,48]. How-
ever, our results showed elevated IL-6 and IL-2 in
mothers bearing a child with DD but not autism. There-
fore, we propose that elevated levels of these cytokines
have a global effect on neurodevelopment, resulting in
cognitive impairment but not necessarily autism.
Maternal cytokines and fetal neurodevelopment
The mechanism by which maternal cytokines affect fetal
neurodevelopment is unclear, though the central nervous
system (CNS) and immune system interact extensively
during fetal development and throughout life. Neuroim-
mune cross-talk is facilitated by shared signaling
pathways and commingling of cellular and soluble com-
ponents from each system [49,50]. Evidence suggests that
immune components such as cytokines can affect aspects
of neurogenesis, neuronal migration and synaptic
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Figure 5 Midgestational serum IL-2. Scatterplots of natural log-
transformed levels of serum IL-2 in mothers bearing a child with
autism spectrum disorder (AU) or a developmental disability other
than ASD (DD) compared with a general population control (GP).
Each dot represents a single individual. Bars represent the medians
and interquartile ranges.
Goines et al. Molecular Autism 2011, 2:13
http://www.molecularautism.com/content/2/1/13
Page 8 of 11plasticity, depending on the timing and level of exposure
[46,51,52]. The developing CNS is especially vulnerable
to immunological and environmental influences because
the fetus has an immature blood-brain barrier and lim-
ited capacity for detoxification and excretion [53]. Under
normal circumstances, the placenta forms a barrier
between the maternal and fetal circulation, though some
maternal immune factors, including IgG and IL-6, are
permitted to cross the placenta [22,54,55]. When passage
of maternal immune components is blocked, the placenta
may respond to entities at the maternal-fetal interface
and alter the fetal compartment [56]. For example, IFN-g
is not known to pass between the maternal and fetal cir-
culation, though IFN-g and its receptors are expressed by
maternal and fetal cells at the maternal-fetal interface
[57]. Therefore, maternal immune components can inter-
act with fetal development both directly and indirectly.
The specific neurodevelopmental impact of the different
cytokine profiles observed in the present study remains
to be determined.
Study limitations
Although our study provides valuable, temporally relevant
information regarding prenatal immune status and the
child’s developmental outcome, a few primary limitations
must be considered. First, immune activation in the per-
ipheral blood is not necessarily representative of immune
activity at the maternal-fetal interface. Examination of
more spatially relevant immune parameters would require
placental or amniotic specimens, which were not available
in this study. Despite this limitation, the archived serum
samples examined provide valuable insight into global
maternal immune status during a developmentally relevant
window. Second, this study is cross-sectional, as the serum
specimens represent a single time point between 15 and
19 weeks of gestation. Maternal immune activity is likely
to change throughout pregnancy, and the gestational
immune environment outside 15 to 19 weeks’ gestation is
also developmentally relevant. Future longitudinal studies
will provide a more complete picture of the relationship
between maternal immune activation throughout preg-
nancy and fetal neurodevelopment. Third, data regarding
the occurrence of infection, allergy and asthma were not
available for the population included in this study, so the
factors underlying the observed cytokine profiles are
unknown. Replication studies are required to further verify
the findings described herein. Fourth, it should be noted
that the study groups were matched on the basis of child
characteristics rather than maternal characteristics. How-
ever, two of the three offspring characteristics used for
matching, birth month and birth year, relate directly to an
important characteristic of the mother (that is, season dur-
ing midpregnancy) that may influence cytokine levels
through their association with seasonal illness. While the
remaining covariates were adjusted for in multivariable
logistic regression analysis, there is a possibility that our
results could be biased because of residual confounding.
Finally, diagnoses were made on the basis of medical
record abstraction rather than via direct assessment.
While we are confident in the consistency and accuracy of
our expert medical record review, we recognize that this
approach is likely to introduce some level of error, in part
because of the differences in the amount and specificity of
documentation in the medical records. Our future analyses
will involve direct observation and diagnosis of subjects.
Conclusions
In conclusion, we describe different midgestational
immune profiles in mothers bearing children with ASD
and mothers bearing children with DD. Mothers bearing
children with autism had cytokine profiles that may be
consistent with an allergy and/or asthma immune pheno-
type, while mothers bearing children with DD but not
autism demonstrated a more inflammatory phenotype.
Cytokines and other immune components are known to
affect the health of pregnancy and can influence fetal
Table 4 Pearson correlation coefficients of cytokines measured in maternal midpregnancy serum in the Early Markers
for Autism study
a
Measurements ASD
(N =8 4
ASD regression
(N = 17)
Early-onset ASD
(N = 64)
ASD with ID
(N = 34)
ASD without ID
(N = 30)
DD
(N = 49)
GP
(N = 159)
Cytokines elevated in
ASD
IFN-g and IL-4 0.95** 0.95** 0.81** 0.98** 0.97** 0.05 0.48**
IFN-g and IL-5 0.73** 0.97** 0.55** 0.91** 0.87** -0.07 0.38**
IL-4 and IL-5 0.72** 0.89** 0.83** 0.97** 0.82** 0.41** 0.77**
Cytokines elevated in
DD
IL-2 and IL-4 0.87** 0.72** 0.62** 0.97** 0.78** 0.57** 0.43**
IL-2 and IL-6 0.02 0.34 0.18 -0.06 0.34 -0.15 0.24**
IL-4 and IL-6 0.15 0.46 0.34* -0.09 0.42* 0.13 0.11
aASD: autism spectrum disorder; ID: intellectual disability; DD: developmental delay; GP: general population. **P < 0.0001, *P < 0.05.
Goines et al. Molecular Autism 2011, 2:13
http://www.molecularautism.com/content/2/1/13
Page 9 of 11neurodevelopment. The possibility that divergent mater-
nal immune profiles during pregnancy have different
effects on fetal neurodevelopment warrants further
investigation.
Additional material
Additional file 1: Adjusted odds ratios for covariates. Adjusted odds
ratios for each covariate analyzed in the subject population for selected
analytes from Table 3.
Additional file 2: Crude odds ratios. Crude unadjusted odds ratios for
all analytes in Table 3.
Additional file 3: Limit of detection. Numbers and percentages of
subjects found to be below the limit of detection (<LOD) for each
analyte across groups.
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